89bio, Inc.
ETNB
$8.47
$0.293.55%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 40.56% | 32.40% | 18.81% | 58.39% | 20.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 196.09% | 286.17% | 26.84% | 100.80% | 62.47% |
| Operating Income | -196.09% | -286.17% | -26.84% | -100.80% | -62.47% |
| Income Before Tax | -224.73% | -328.71% | -24.60% | -78.89% | -47.92% |
| Income Tax Expenses | -93.35% | -- | -- | -- | 24,068.75% |
| Earnings from Continuing Operations | -194.16% | -329.30% | -24.95% | -79.22% | -63.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -194.16% | -329.30% | -24.95% | -79.22% | -63.54% |
| EBIT | -196.09% | -286.17% | -26.84% | -100.80% | -62.47% |
| EBITDA | -196.18% | -286.25% | -26.84% | -100.87% | -62.50% |
| EPS Basic | -104.71% | -206.05% | 7.22% | 0.57% | -2.97% |
| Normalized Basic EPS | -118.34% | -205.66% | 7.48% | -1.03% | 4.96% |
| EPS Diluted | -104.71% | -206.05% | 7.22% | 0.57% | -2.97% |
| Normalized Diluted EPS | -118.34% | -205.66% | 7.48% | -1.03% | 4.96% |
| Average Basic Shares Outstanding | 43.69% | 40.27% | 34.68% | 80.26% | 58.82% |
| Average Diluted Shares Outstanding | 43.69% | 40.27% | 34.68% | 80.26% | 58.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
